AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Companion Diagnostic indication of Amivantamab plus Lazertinib combination Therapy

TOKYO and XIAMEN, July 23, 2025 — Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”) as a companion diagnostic (CDx) for indication of Amivantamab plus Lazertinib combination Therapy in Japan.

Read the full release here.

JointRelease_EGFR_AmiLaz_PLC_RG-Amoy-PREMIA.pdf

Download PDF • 232KB